MIT study reveals the problem with bioresorbable stents

Image courtesy of Pei-Jiang Wang

Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX).

But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb product from the market and Boston Scientific to terminate its Renuvia scaffold development program last year.

Get the full story at our sister site, Drug Delivery Business News.

The post MIT study reveals the problem with bioresorbable stents appeared first on MassDevice.

from MassDevice http://ift.tt/2FJlieU